Publications by authors named "J X Sosa"

Background: Our group and others have recently identified four molecular groups of meningioma, with unique underlying biology and outcomes. The relevance of group-specific metabolite profiles (particularly among hypermetabolic tumours), has not been explored.

Methods: We performed untargeted metabolic profiling of meningiomas representing each molecular group and WHO grade.

View Article and Find Full Text PDF

Background: Meningiomas exhibit considerable clinical and biological heterogeneity. We previously identified four distinct molecular groups (immunogenic, NF2-wildtype, hypermetabolic, proliferative) that address much of this heterogeneity. Despite the utility of these groups, the stochasticity of clustering methods and the use of multi-omics data for discovery limits the potential for classifying prospective cases.

View Article and Find Full Text PDF

From the perspective of chair, there is essential work to do before designating a vice chair, leader, and/or advocate for departmental inclusivity, and that is to work to create a departmental culture that values diversity, embraces different worldviews, and includes a variety of different perspectives. It is important to empower and resource with protected time and budget a vice chair who can be active and intentional day in and day out to create, maintain (and hopefully expand) an inclusive community. Their work should be augmented with a committee inclusive of staff, faculty, and trainees who can provide feedback and creative ideas.

View Article and Find Full Text PDF
Article Synopsis
  • - The study validates a new DNA methylation-based predictor for meningiomas that has been enhanced for use with modern methylation arrays and shows improved accuracy over the standard 2021 WHO grading system.
  • - It uses data from 1,347 meningioma cases, including prospective cases and an external cohort, demonstrating that both the new and original models effectively predict early postoperative recurrence, especially within specific risk subgroups.
  • - The new predictor, which is simpler with fewer features, allows for better clinical decision-making, including the use of adjuvant radiotherapy for high-risk patients, and is available as an easy-to-use tool for improved patient stratification in clinical trials.
View Article and Find Full Text PDF